TrialEuropean urology2016

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

Matthew R Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.